Results 81 to 90 of about 56,178 (231)
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source
An in vivo biosensor for neurotransmitter release and in situ receptor activity. [PDF]
, 2010 Tools from molecular biology, combined with in vivo optical imaging techniques, provide new mechanisms for noninvasively observing brain processes. Current approaches primarily probe cell-based variables, such as cytosolic calcium or membrane potential ...
Griesbeck, Oliver +6 more
core +2 more sources
PM&R, EarlyView.Abstract Background and Objective Previous work from this dataset found 45% prescribing frequency of any medications (35.1%, 33.5%, and 56.8% at institutions 1, 2, and 3 respectively), without significant difference between in‐person and telemedicine.
Matthew Chen +7 more
wiley +1 more source
The Effect of Olanzapine on Craving and Alcohol Consumption
, 2006 Previous studies have indicated that olanzapine decreases craving after a priming dose of alcohol, that craving after a priming dose of alcohol is greater among individuals with the seven-repeat allele of the DRD4 variable number of tandem repeats (VNTR)
Davidson, Dena +6 more
core
Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials [PDF]
, 2017 This study was a meta-analysis of randomized controlled trials (RCTs) of ranitidine as an adjunct for antipsychotic-induced weight gain in patients with schizophrenia.
Chen, Rui +13 more
core +3 more sources
Polypharmacy among adolescents and adults with cerebral palsy in a clinical setting
PM&R, EarlyView.Abstract Background Adolescents and adults with cerebral palsy often experience multimorbidity related to their condition, which primarily affects movement and posture but is also associated with pain, epilepsy, mood disorders, and other conditions. As such, these patients are often prescribed a range of medications to manage symptoms, thereby putting ...
Caitlin Cassidy +3 more
wiley +1 more source
Nanoemulsion-based nasal in situ gel of olanzapine.
Journal of Excipients and Food Chemicals, 2023 Oral delivery of olanzapine suffers from low oral bioavailability and there has been reports of metabolic side effects. This study aimed to prepare a nanoemulsion of olanzapine and incorporate it into an in situ gel for nasal delivery.
Zahraa H Ali, Myasar Alkotaji
doaj
Olanzapine Attenuates Cue-elicited Craving for Tobacco
, 2004 Rationale: Recent biological conceptualizations of craving and addiction have implicated mesolimbic dopamine activity as a central feature of the process of addiction. Imaging, and pharmacological studies have supported a role for dopaminergic structures
Hutchinson, Kent E +5 more
core
Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition. [PDF]
, 2018 Candidate pro-cognitive drugs for schizophrenia targeting several neurochemical systems have consistently failed to demonstrate robust efficacy. It remains untested whether concurrent antipsychotic medications exert pharmacodynamic interactions that ...
Carter, Cameron S +3 more
core +3 more sources
Acta Psychiatrica Scandinavica, EarlyView.ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios +17 more
wiley +1 more source